Ajuben – Deutetrabenazine

Home / Ajuben – Deutetrabenazine

Ajuben

12 mg Tablet
Deutetrabenazine · Incepta Pharmaceuticals Ltd.
EN বাং
৳130.00
per unit
AI Summary Generated by AI for informational purposes only

এই ওষুধটি হান্টিংটন ডিজিজের মতো রোগের কারণে সৃষ্ট শরীরের অনৈচ্ছিক নড়াচড়া বা ঝাঁকুনির চিকিৎসায় ব্যবহৃত হয়। এটি মস্তিষ্কের ওপর কাজ করে এই নড়াচড়া নিয়ন্ত্রণ করে। গর্ভাবস্থায় এটি নিরাপদ নয় এবং চিকিৎসা চলাকালীন স্তন্যদান করার পরামর্শ দেওয়া হয় না।

Indications

Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of-
  • Chorea associated with Huntington's disease
  • Tardive dyskinesia in adults.

Pharmacology

The precise mechanism by which deutetrabenazine exerts its anti-chorea effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine and β-dihydrotetrabenazine) of deutetrabenazine, are reversible inhibitors of vesicular monoamine transporter 2 (VMAT2), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.

Dosage & Administration

Important:
Do not take any medication without a doctor's prescription. Self-medication can be dangerous.
Patients not presently receiving Tetrabenazine:

Chorea associated with Huntington’s disease-
  • Initial dose: 6 mg/day
  • Maintenance dose: 6 mg-48 mg/day
  • Maximum dose: 48 mg/day
Tardive dyskinesia-
  • Initial dose: 12 mg/day
  • Maintenance dose: 12 mg-48 mg/day
  • Maximum dose: 48 mg/day
Titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Administer total daily dosages of 12 mg or above in two divided doses and administer with foods.

Patients receiving Tetrabenazine: If switching patients from tetrabenazine, discontinue tetrabenazine and initiate deutetrabenazine the following day. The recommended initial dosing regimen of deutetrabenazine in patients switching from tetrabenazine to deutetrabenazine is shown in below chert:
 
Current Tetrabenazine daily dosage Initial regimen of Deutetrabenazine
12.5 mg 6 mg once daily
25 mg 6 mg once daily
37.5 mg 9 mg once daily
50 mg 12 mg once daily
62.5 mg 15 mg once daily
75 mg 18 mg once daily
87.5 mg 21 mg once daily
100 mg 24 mg once daily
After patients are switched to deutetrabenazine, the dose may be adjusted at weekly intervals.

Interaction

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of deutetrabenazine is 36 mg per day (18 mg twice daily) and alcohol or other sedating drugs- may have additive sedation and somnolence.

Contraindications

Deutetrabenazine is contraindicated in patients with Suicidal, or untreated/inadequately treated depression, Hepatic impairment and in patients Taking MAOIs, reserpine, or tetrabenazine.

Side Effects

Most common adverse reactions (>8%) of deutetrabenzine’s are somnolence, diarrhea, dry mouth, and fatigue.

Pregnancy & Lactation

There are no adequate data on the developmental risk associated with the use of deutetrabenazine in pregnant women. There are no data on the presence of deutetrabenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.

Precautions & Warnings

Patients may experience Neuroleptic Malignant Syndrome (discontinue deutetrabenazine if this occurs), Akathisia, agitation, restlessness, and Parkinsonism (reduce the daily dose of deutetrabenazine or discontinue if this occurs) and Sedation/somnolence.

Use in Special Populations

Use in Children: Safety & effectiveness of deutetrabenzine in infants & children have not been established.

Patients with Hepatic & Renal Impairment: No clinical studies have been conducted to assess the effect of renal & hepatic impairment on the pharmacokinetics of deutetrabenazine.

Patients with poor CYP2D6 metabolizers: Maximum recommended dosage of deutetrabenazine in poor CYP2D6 metabolizers is 36 mg per day (i.e., 18 mg twice daily)

Overdose Effects

The following adverse reactions occurred with overdosing: acute dystonia, oculogyric crisis, nausea and vomiting, sweating, sedation, hypotension, confusion, diarrhea, hallucinations, rubor, and tremor.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

The information provided on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. All brands listed might have copyright or trademark of their respective owners. Listed information may not be up-to-date or accurate. We do not guarantee the availability, quality, price or safety of any medication. Use at your own risk.

Similar Brands

1 found
Brand Strength ৳
Ajuben
Incepta Pharmaceuticals Ltd.
6 mg 70.00